The interruption of romosozumab treatment during COVID lockdown among US post-menopausal women enrolled in Medicare
Description
CONCLUSION: Compared to the pre-COVID period, the lockdown negatively impacted the continuity of romosozumab treatment among Medicare beneficiaries. Prioritizing in-time assistance for patients receiving a provider-administered parenteral therapy is
